November 25th 2024
Fluorescence spectroscopy offers unique advantages for characterizing EVs.
November 22nd 2024
November 21st 2024
The evolution of therapeutic modalities drives the adoption of single-use technologies.
FDA Approves ADMA Biologics’ Expanded Manufacturing Process for Intravenous Immune Globulin
April 29th 2021ADMA will now have the ability to produce Bivigam at an expanded capacity with the same manufacturing scale, while using the same equipment, release testing assays, disposables, and labor force.
Cytiva Provides Another FlexFactory Single-Use Platform for AkesoBio’s Manufacturing Expansion
April 27th 2021AkesoBio’s expanded manufacturing capacity, enabled by the addition of another Cytiva FlexFactory platform, will be used to meet current and future market needs in China as well as worldwide.
DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA
April 27th 2021With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Agreement for $1.1 Billion
April 21st 2021Vertex and CRISPR have amended their collaboration agreement to include the development, manufacture, and commercialization of CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
China Approves BeiGene for Commercial Manufacturing at its Biologics Facility
April 8th 2021The China National Medical Products Administration has given the company the green light to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China.
Many biologic drug manufacturers encounter similiar challenges; precompetitive collaboration can help resolve these issues. Representatives of the IQ Consortium’s Biologics CMC Leadership Group describe efforts to address the safe handling of biologic drugs in closed-system transfer devices in healthcare settings and the need for phase-appropriate specifications.